IN8bio cleared for glioblastoma Phase 2

 IN8bio, Inc. today announced that it has received received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial of a genetically modified autologous gamma-delta T cell therapy (INB-400) targeting newly diagnosed glioblastoma (GBM).

https://www.biospace.com/article/releases/in8bio-announces-fda-clearance-to-initiate-a-phase-2-clinical-trial-of-inb-400-gamma-delta-t-cells-for-glioblastoma/